John T. Isaacs - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Pharmaceutical Chemistry, Cell Biology

101 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine. 7: S311. PMID 32016030 DOI: 10.21037/atm.2019.10.32  0.68
2019 Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine. PMID 30925030 DOI: 10.1002/sctm.19-0068  0.68
2019 Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology. 6: 99-108. PMID 30775253 DOI: 10.1016/j.ajur.2018.11.004  0.68
2019 Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/sctm.18-0230  0.68
2018 Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine. PMID 30070053 DOI: 10.1002/sctm.18-0024  0.68
2017 Isaacs JT, Brennen WN, Denmeade SR. Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28820291 DOI: 10.1080/15384101.2017.1360645  0.68
2017 Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/oncotarget.17362  0.68
2016 Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT. Low p16(INK4a) Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone. The Prostate. PMID 27859428 DOI: 10.1002/pros.23276  0.4
2016 Guedes L, Morais C, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27166397 DOI: 10.1158/1078-0432.CCR-16-0205  0.68
2016 Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, ... Isaacs JT, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91: 140-150. PMID 27019026 DOI: 10.1016/j.biomaterials.2016.03.023  0.68
2016 Hedayati M, Haffner MC, Coulter J, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Dalrymple S, Isaacs JT, Santos A, Hales RK, Razavi N, Nelson WG, Yegnasubramanian S, et al. Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26831716 DOI: 10.1158/1078-0432.CCR-15-1147  0.68
2016 Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. The Prostate. PMID 26732992 DOI: 10.1002/pros.23145  0.68
2015 Isaacs JT. Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene. The American Journal of Pathology. 185: 614-6. PMID 25700984 DOI: 10.1016/j.ajpath.2015.01.001  0.68
2015 Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 7: 269ra2. PMID 25568070 DOI: 10.1126/scitranslmed.3010563  0.68
2015 Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB. Targeting thapsigargin towards tumors. Steroids. 97: 2-7. PMID 25065587 DOI: 10.1016/j.steroids.2014.07.009  0.68
2014 Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 5: 8093-106. PMID 25193858  0.68
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 371: 1028-38. PMID 25184630 DOI: 10.1056/NEJMoa1315815  0.68
2014 Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. The Prostate. 74: 1308-19. PMID 25053236 DOI: 10.1002/pros.22847  0.68
2014 Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. International Journal of Biological Sciences. 10: 627-42. PMID 24948876 DOI: 10.7150/ijbs.8756  0.68
2014 Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription. The Prostate. 74: 1118-31. PMID 24913829 DOI: 10.1002/pros.22828  0.68
2014 Akinboye ES, Butcher RJ, Yildirim SO, Isaacs JT. 4-Hy-droxy-5-meth-oxy-N,1-dimethyl-2-oxo-N-[4-(tri-fluoro-meth-yl)phen-yl]-1,2-di-hydro-quinoline-3-carboxamide. Acta Crystallographica. Section E, Structure Reports Online. 70: o297-8. PMID 24765003 DOI: 10.1107/S1600536814003031  0.68
2014 Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Research. 74: 3390-5. PMID 24747912 DOI: 10.1158/0008-5472.CAN-14-0249  0.68
2014 Regter S, Hedayati M, Zhang Y, Zhou H, Dalrymple S, Koch CJ, Isaacs JT, DeWeese TL. Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. The Prostate. 74: 805-10. PMID 24677180 DOI: 10.1002/pros.22803  0.68
2013 Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer. 20: R269-90. PMID 23975882 DOI: 10.1530/ERC-13-0151  0.68
2013 Isaacs JT. Cancer. Prostate cancer takes nerve. Science (New York, N.Y.). 341: 134-5. PMID 23846894 DOI: 10.1126/science.1241776  0.68
2013 Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. The Prostate. 73: 1316-25. PMID 23775398 DOI: 10.1002/pros.22677  0.68
2013 Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 4: 106-17. PMID 23362217 DOI: 10.18632/oncotarget.805  0.68
2013 Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research. 73: 1386-99. PMID 23149916 DOI: 10.1158/0008-5472.CAN-12-2730  0.68
2012 Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute. 104: 1320-34. PMID 22911669 DOI: 10.1093/jnci/djs336  0.68
2012 Denmeade SR, Isaacs JT. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget. 3: 666-7. PMID 22837432 DOI: 10.18632/oncotarget.562  0.68
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, ... Isaacs JT, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/scitranslmed.3003886  0.68
2012 Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate. 72: 1491-505. PMID 22396319 DOI: 10.1002/pros.22504  0.68
2012 Chen S, Principessa L, Isaacs JT. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. The Prostate. 72: 1478-89. PMID 22396312 DOI: 10.1002/pros.22503  0.68
2012 Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics. 11: 257-66. PMID 22323494 DOI: 10.1158/1535-7163.MCT-11-0340  0.68
2012 Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. The Prostate. 72: 638-48. PMID 21837778 DOI: 10.1002/pros.21467  0.68
2011 Sfanos KS, Isaacs JT. The "infectious" nature of human prostate cancer: a cautionary note. Oncotarget. 2: 281-3. PMID 21521904 DOI: 10.18632/oncotarget.267  0.68
2011 Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. The Prostate. 71: 1595-607. PMID 21394741 DOI: 10.1002/pros.21375  0.68
2010 Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion On Investigational Drugs. 19: 1235-43. PMID 20836618 DOI: 10.1517/13543784.2010.514262  0.68
2010 D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. Plos One. 5: e11475. PMID 20628607 DOI: 10.1371/journal.pone.0011475  0.68
2010 Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. The Prostate. 70: 1600-7. PMID 20607766 DOI: 10.1002/pros.21196  0.68
2010 Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer. 9: 107. PMID 20470445 DOI: 10.1186/1476-4598-9-107  0.68
2010 Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. The Prostate. 70: 788-96. PMID 20058238 DOI: 10.1002/pros.21111  0.68
2010 Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. The Prostate. 70: 90-9. PMID 19790235 DOI: 10.1002/pros.21043  0.68
2009 Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 77: 984-93. PMID 19705489 DOI: 10.1002/prot.22524  0.68
2009 Sedelaar JP, Isaacs JT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. The Prostate. 69: 1724-9. PMID 19676093 DOI: 10.1002/pros.21028  0.68
2009 Vander Griend DJ, Konishi Y, De Marzo AM, Isaacs JT, Meeker AK. Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. The Prostate. 69: 1557-64. PMID 19562732 DOI: 10.1002/pros.21001  0.68
2009 Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics. 8: 1340-9. PMID 19417145 DOI: 10.1158/1535-7163.MCT-08-1136  0.68
2009 Ishioka J, Hara S, Isaacs JT, Tomura A, Nishikawa K, Kageyama Y. Suppression of mutant androgen receptors by flutamide. International Journal of Urology : Official Journal of the Japanese Urological Association. 16: 516-21. PMID 19389135 DOI: 10.1111/j.1442-2042.2009.02284.x  0.68
2009 Madar I, Huang Y, Ravert H, Dalrymple SL, Davidson NE, Isaacs JT, Dannals RF, Frost JJ. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 774-80. PMID 19372481 DOI: 10.2967/jnumed.108.061283  0.68
2009 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 48: 3490-6. PMID 19281249 DOI: 10.1021/bi9001858  0.68
2009 Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 9: 276-94. PMID 19275521  0.68
2009 D'Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocrine-Related Cancer. 16: 325-32. PMID 19240183 DOI: 10.1677/ERC-08-0205  0.68
2009 Shelfer LF, Isaacs JT. The alchemy of Jargon: etymologies of urologic neologisms: number 1--introduction to the series. The Prostate. 69: 225-7. PMID 18991247 DOI: 10.1002/pros.20874  0.68
2008 Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Research. 68: 9703-11. PMID 19047148 DOI: 10.1158/0008-5472.CAN-08-3084  0.68
2008 Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. The Prostate. 68: 1570-81. PMID 18668523 DOI: 10.1002/pros.20821  0.68
2008 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology. 15: 665-74. PMID 18635003 DOI: 10.1016/j.chembiol.2008.05.020  0.68
2008 Isaacs JT. Prostate stem cells and benign prostatic hyperplasia. The Prostate. 68: 1025-34. PMID 18386293 DOI: 10.1002/pros.20763  0.68
2008 Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, et al. The current state of preclinical prostate cancer animal models. The Prostate. 68: 629-39. PMID 18213636 DOI: 10.1002/pros.20726  0.68
2008 Singh P, Williams SA, Shah MH, Lectka T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins. 70: 1416-28. PMID 17894328 DOI: 10.1002/prot.21676  0.68
2007 Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033  0.68
2007 Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorganic & Medicinal Chemistry. 15: 4973-84. PMID 17502149 DOI: 10.1016/j.bmc.2007.04.029  0.68
2007 Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle (Georgetown, Tex.). 6: 647-51. PMID 17387277  0.68
2007 Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. The Prostate. 67: 799-807. PMID 17373727 DOI: 10.1002/pros.20542  0.68
2007 Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. The Prostate. 67: 790-7. PMID 17373719 DOI: 10.1002/pros.20573  0.68
2007 Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. Journal of the National Cancer Institute. 99: 376-85. PMID 17341729 DOI: 10.1093/jnci/djk065  0.68
2007 Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? The Prostate. 67: 312-29. PMID 17143882 DOI: 10.1002/pros.20531  0.68
2006 Liu H, Jensen KG, Tran LM, Chen M, Zhai L, Olsen CE, Søhoel H, Denmeade SR, Isaacs JT, Christensen SB. Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica. Phytochemistry. 67: 2651-8. PMID 17098264 DOI: 10.1016/j.phytochem.2006.10.005  0.68
2006 Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 15085-90. PMID 17015840 DOI: 10.1073/pnas.0603057103  0.68
2006 Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Research. 66: 9171-7. PMID 16982760 DOI: 10.1158/0008-5472.CAN-06-1520  0.68
2006 Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate. 66: 1768-78. PMID 16955399 DOI: 10.1002/pros.20509  0.68
2006 Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer. 13: 653-66. PMID 16954423 DOI: 10.1677/erc.1.00797  0.68
2006 Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Research. 66: 8598-607. PMID 16951173 DOI: 10.1158/0008-5472.CAN-06-1228  0.68
2006 Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Research. 66: 7509-15. PMID 16885348 DOI: 10.1158/0008-5472.CAN-05-3048  0.68
2006 Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. The Prostate. 66: 1329-38. PMID 16835890 DOI: 10.1002/pros.20483  0.68
2006 Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4072-9. PMID 16818707 DOI: 10.1158/1078-0432.CCR-06-0184  0.68
2006 Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Benzoylphenylurea sulfur analogues with potent antitumor activity. Journal of Medicinal Chemistry. 49: 2357-60. PMID 16570932 DOI: 10.1021/jm051261s  0.68
2006 Søhoel H, Jensen AM, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE, Christensen SB. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorganic & Medicinal Chemistry. 14: 2810-5. PMID 16412648 DOI: 10.1016/j.bmc.2005.12.001  0.68
2006 Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. The Prostate. 66: 358-68. PMID 16302271 DOI: 10.1002/pros.20348  0.68
2005 Isaacs JT. New strategies for the medical treatment of prostate cancer. Bju International. 96: 35-40. PMID 16359437 DOI: 10.1111/j.1464-410X.2005.05945.x  0.68
2005 Søhoel H, Liljefors T, Ley SV, Oliver SF, Antonello A, Smith MD, Olsen CE, Isaacs JT, Christensen SB. Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin. Journal of Medicinal Chemistry. 48: 7005-11. PMID 16250659 DOI: 10.1021/jm058036v  0.68
2005 Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Research. 65: 9269-79. PMID 16230388 DOI: 10.1158/0008-5472.CAN-04-3989  0.68
2005 Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. Androgens and prostate cancer: are the descriptors valid? Cancer Biology & Therapy. 4: 4-5. PMID 16052746  0.68
2005 Burnett AL, Kramer MF, Dalrymple S, Isaacs JT. Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells. Urology. 65: 1003-7. PMID 15882753 DOI: 10.1016/j.urology.2004.11.033  0.68
2005 Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. Journal of Medicinal Chemistry. 48: 3005-14. PMID 15828839 DOI: 10.1021/jm049319a  0.68
2005 Uzgare AR, Isaacs JT. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. The International Journal of Biochemistry & Cell Biology. 37: 707-14. PMID 15694830 DOI: 10.1016/j.biocel.2004.11.018  0.68
2005 Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biology & Therapy. 4: 14-22. PMID 15662118  0.68
2004 Litvinov IV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. The Prostate. 61: 299-304. PMID 15499637 DOI: 10.1002/pros.20187  0.68
2004 Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 431: 707-12. PMID 15361885 DOI: 10.1038/nature02962  0.68
2004 Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Research. 64: 6190-9. PMID 15342404 DOI: 10.1158/0008-5472.CAN-04-0968  0.68
2004 Litvinov IV, Chang C, Isaacs JT. Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. The Prostate. 58: 319-24. PMID 14968432 DOI: 10.1002/pros.20027  0.68
2004 Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. The Prostate. 58: 211-24. PMID 14743459 DOI: 10.1002/pros.10360  0.68
2004 Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nature Medicine. 10: 26-7. PMID 14702629 DOI: 10.1038/nm0104-26  0.68
2004 Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. Journal of Cellular Biochemistry. 91: 196-205. PMID 14689591 DOI: 10.1002/jcb.10764  0.68
2003 Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D, Isaacs JT. Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. The Prostate. 57: 256-60. PMID 14601021 DOI: 10.1002/pros.10309  0.68
2003 Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? The Journal of Clinical Endocrinology and Metabolism. 88: 2972-82. PMID 12843129 DOI: 10.1210/jc.2002-022038  0.68
2003 Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute. 95: 990-1000. PMID 12837835  0.68
2003 Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate. 56: 45-53. PMID 12746846 DOI: 10.1002/pros.10213  0.68
2003 Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. 54: 249-57. PMID 12539223 DOI: 10.1002/pros.10199  0.68
2002 Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 12: 2459-61. PMID 12161157 DOI: 10.1016/S0960-894X(02)00433-X  0.68
2002 Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature Reviews. Cancer. 2: 389-96. PMID 12044015 DOI: 10.1038/nrc801  0.68
2002 Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Research. 62: 986-9. PMID 11861369  0.68
Show low-probability matches.